The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.
A. Ardizzoni
No relevant relationships to disclose
L. Boni
No relevant relationships to disclose
M. Tiseo
No relevant relationships to disclose
A. Vincent
No relevant relationships to disclose
R. Passalacqua
No relevant relationships to disclose
A. Camerini
No relevant relationships to disclose
R. Labianca
No relevant relationships to disclose
G. Genestreti
No relevant relationships to disclose
F. Zanelli
No relevant relationships to disclose
L. Ciuffreda
No relevant relationships to disclose
F. Di Costanzo
No relevant relationships to disclose
F. De Marinis
No relevant relationships to disclose
L. Crinò
No relevant relationships to disclose
A. Santo
No relevant relationships to disclose
A. Pazzola
No relevant relationships to disclose
F. Barbieri
No relevant relationships to disclose
N. Zilembo
No relevant relationships to disclose
I. Colantonio
No relevant relationships to disclose
C. Tibaldi
No relevant relationships to disclose
E. F. Smit
No relevant relationships to disclose